EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification and validation of an anoikis-related lncRNA signature to predict prognosis and immune landscape in osteosarcoma

Jun-Song Zhang, Run-Sang Pan, Xiao-Bin Tian

Frontiers in Oncology · 23.03.2023 · 13

DOI: 10.3389/fonc.2023.1156663 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 23.03.2023. Verfasst von Jun-Song Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Guizhou Medical University, Guiyang, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anoikis is a specialized form of programmed apoptosis that occurs in two model epithelial cell lines and plays an important role in tumors. However, the prognostic value of anoikis-related lncRNA (ARLncs) in osteosarcoma (OS) has not been reported.

Methods

Based on GTEx and TARGET RNA sequencing data, we carried out a thorough bioinformatics analysis. The 27 anoikis-related genes were obtained from the Gene Set Enrichment Analysis (GSEA). Univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analysis were successively used to screen for prognostic-related ARLncs. To create the prognostic signature of ARLncs, we performed multivariate Cox regression analysis. We calculated the risk score based on the risk coefficient, dividing OS patients into high- and low-risk subgroups. Additionally, the relationship between the OS immune microenvironment and risk prognostic models was investigated using function enrichment, including Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), single-sample gene set enrichment analysis (ssGSEA), and GSEA analysis. Finally, the potential effective drugs in OS were found by immune checkpoint and drug sensitivity screening.

Results

A prognostic signature consisting of four ARLncs (AC079612.1, MEF2C-AS1, SNHG6, and TBX2-AS1) was constructed. To assess the regulation patterns of anoikis-related lncRNA genes, we created a risk score model. According to a survival analysis, high-risk patients have a poor prognosis as they progress. By using immune functional analysis, the lower-risk group demonstrated the opposite effects compared with the higher-risk group. GO and KEGG analysis showed that the ARLncs pathways and immune-related pathways were enriched. Immune checkpoints and drug sensitivity analysis might be used to determine the better effects of the higher group.

Conclusion

We identified a novel prognostic model based on a four-ARLncs signature that might serve as potential prognostic indicators that can be used to predict the prognosis of OS patients, and immunotherapy and drugs that may contribute to improving the overall survival of OS patients and advance our understanding of OS.

Schlagwörter

Stichwörter der Autor:innen

anoikisimmunelncRNAosteosarcomaprognosis

Autor:innen und Institutionen

  • School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
  • School of Basic Medicine, Guizhou Medical University, Guiyang, China.
  • Department of Orthopedics, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Zitieren

APA

Zhang, J. S., Pan, R. S., & Tian, X. B. (2023). Identification and validation of an anoikis-related lncRNA signature to predict prognosis and immune landscape in osteosarcoma. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1156663

Vancouver

Zhang JS, Pan RS, Tian XB. Identification and validation of an anoikis-related lncRNA signature to predict prognosis and immune landscape in osteosarcoma. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1156663

BibTeX
@article{Zhang2023,
  author = {Zhang, Jun-Song and Pan, Run-Sang and Tian, Xiao-Bin},
  title = {Identification and validation of an anoikis-related lncRNA signature to predict prognosis and immune landscape in osteosarcoma},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1156663}
}
Kostenlos starten →